State Agency Directory | Online Services

Drug Utilization Review 

The primary objectives of Drug Utilization Review (DUR) are to improve the quality of health care for Medicaid members and to assist in containing health care costs.   In order to achieve these goals, prescription claims must be reviewed both prospectively and retrospectively.   Findings of the reviews are communicated to both prescribers and pharmacists to assure that medications provided are appropriate, medically necessary, and not likely to result in adverse medical effects.    Drug Utilization Review is mandated by the Omnibus Budget Reconciliation Act of 1990 (OBRA ’90), an amendment to the Social Security Act.

Calendar, Agendas and Minutes  

All meetings are held from 4-6 pm in the Lower Level Conference Room of the DHHR Building at 350 Capitol Street, Charleston, WV. 
Contact:  Vicki Cunningham, R. Ph.
               Drug Utilization Review Coordinator
               304-558-1700
               Vicki.M.Cunningham@wv.gov

2013 Meetings
November 20, 2013
September 18, 2013
May 15, 2013		Agenda
February 20, 2013		Agenda	Minutes	Bipolar Proposal Bipolar Letter Diabetes Numbers Mental Health News Letter Lock-In Outcome FFY 2012 Mail Merge Approval - Crestor PDL Provider Letter
2012 Meetings
November 28, 2012		Agenda	Minutes	Anticonvulsant Drug Use Evaluation Gastrointestinal Agents DUE Proposal Gastrointestinal Agents DUE Letter Rational Drug Therapy Program Fluoroquinolone Lidoderm Utilization April 2006 - March 2010 Suboxone
September 19, 2012		Agenda	Minutes	Attachment A -  Analgesics, Narcotics Attachment B  Attachment C -  PDL w/PA Criteria Attachment D -  Lyrica Attachment E -  Step Therapy Proposal Attachment F -  Venlafaxine Member Dosage Attachment G -  DUR Presentation Attachment H -  Benzodiazepine Anxiolytic Attachment I   -  DUR Presentation Attachment J  -  Summary Report
May 23, 2012		Agenda	Minutes	Attachment A - Incivek Attachment B - Victrelis Attachment C - Makena Statement Attachment D - PT Meeting Changes Summary Attachment E - Oral Oncology Agents Attachment F - Kayldeco Attachment G - Kuvan Attachment H - Increlex
February 15, 2012		Agenda	Minutes	Attachment A - PDL Changes Attachment G - RDTP Attachment H - ACS Attachment I - Molina  Onfi Rectiv Relistor Rilutek Votrient
2011 Meetings
November 16, 2011		Agenda	Minutes	Attachment - ACS Attachment - RDTP Attachment A - Dificid Attachment B - Humira - Enbrel Attachment C - Incivek Attachment D - Victrelis Attachment E - Gralise Attachment F - 2012 DUR Meetings
September 21, 2011		Agenda	Minutes	Attachment A - RDTP Report Attachment C - Atypical Antipsychotics Attachment D - Letter Butrans Complera Daliresp Dificid Horizant Regranex
May 25, 2011		Agenda	Minutes	Adults Stimulants Atypicals - Children under 6 yrs. Makena Statement Otic Edge Drops Sprycel Updates WV Fibromyalgia Letter WV Fibromyalgia  Proposal WV Narc Prescriber Letter WV PDL DUR Review
March 2, 2011		Agenda	Minutes	Carbaglu Cough/Cold Meds Vivitrol PDL Changes PDL DUR Presentation Multiple Drug Therapy
DUR Archived Agendas and Meetings